Tebonin, known generically as EGb 761, is a standardized extract of Ginkgo biloba that has been extensively studied since its introduction in 1965 for its potential benefits in treating various mental health conditions, including Tardive Dyskinesia (TD).

Tardive Dyskinesia (TD), a potentially permanent movement disorder, is a potential risk associated with the use of atypical antipsychotics, a concern relevant to all patients, irrespective of their age, the dosage, or the specific type of medication used.